Canada Acetaminophen Melatonin Recall – Affected Lots, Risks and Steps

Health Canada issued a Class II recall alert for specific lots of over-the-counter acetaminophen and melatonin products sold at retail locations nationwide. The affected items include Laboratoire Riva Inc.’s Acetaminophen Caplet 500 mg and Life Brand’s Timed Release Melatonin 10 mg tablets, pulled from distribution due to labelling errors that could result in improper dosing.

The recall, designated under alert number RA-77279, targets lot D3120 for the acetaminophen product and seven specific lots for the melatonin supplement. While the errors differ—one involves incorrect tablet strength and the other incorrect dosing instructions—both pose risks of under-treatment or confusion for consumers relying on these medications for pain management and sleep regulation.

What Products Are Affected by the Canada Acetaminophen Melatonin Recall?

Key insights regarding the scope and nature of this recall:

• Two distinct therapeutic categories affected: analgesic (acetaminophen) and sleep aid (melatonin)
• Acetaminophen error involves packaging of lower-strength 325 mg tablets in 500 mg labelled containers
• Melatonin products carry incorrect dosing instructions on the label
• Precise lot numbering allows consumers to verify specific purchased units
• Wide retail distribution increases the potential consumer exposure
• Class II designation indicates a moderate risk level where temporary health effects may occur
• No contamination with foreign substances; defects are strictly labelling and packaging related

Why Was Acetaminophen Melatonin Recalled in Canada?

Health Canada identified labelling discrepancies that could compromise treatment efficacy and consumer safety. The acetaminophen product may contain tablets with 325 mg strength instead of the labelled 500 mg, creating a risk of under-treatment for pain or fever. The melatonin products display incorrect dosing instructions, which could lead to improper sleep aid administration.

The Acetaminophen Strength Discrepancy

The Riva Acetaminophen Caplet packaging indicates a 500 mg dosage per tablet. However, lot D3120 may contain 325 mg tablets instead. This discrepancy means consumers taking the medication as directed on the label would receive less acetaminophen than expected, potentially resulting in inadequate pain relief or insufficient fever reduction. Global News reporting confirms this specific labelling error prompted the recall action.

Melatonin Dosing Instruction Errors

For the Life Brand Timed Release Melatonin 10 mg tablets, the affected lots carry incorrect dosing instructions on the label. While melatonin is generally considered safe for short-term use, improper dosing timing or quantity can disrupt sleep cycles rather than regulate them. Health Canada video statements highlight these labelling inaccuracies as the primary concern.

What Should Consumers Do About the Recalled Acetaminophen Melatonin?

Verifying Lot Numbers

Consumers should immediately check their medicine cabinets for the specific products and lot numbers identified. The acetaminophen lot D3120 and the seven melatonin lots—D3120, 4D3965YA2, 4F4495YA2, 4F44961B0, 4F44962LH, 4H49262LH, and 5C47764ES—should be segregated from other medications. Health Canada’s official recall notice provides visual identifiers for these products.

Medical Consultation Recommendations

Health Canada advises consumers to consult a healthcare provider before discontinuing use abruptly, particularly if the medication was prescribed as part of a broader treatment plan. Do not stop taking any medication without professional guidance. If you have used the affected acetaminophen lot and experienced persistent pain or fever, or if you have used the affected melatonin and experienced unusual sleep disturbances, contact your physician. While maintaining your health routines, you might also consider outdoor activities for wellness; Sleeping Giant Provincial Park – Hiking Trails and Camping Guide offers information on accessible recreational areas.

Report any side effects or safety complaints to Health Canada through their standard reporting channels. Consumers may also contact Laboratoire Riva Inc. directly at 660 boulevard Industriel, Blainville, QC, J7C 3V4, with questions regarding the acetaminophen product.

Which Brands and Distribution Areas Are Involved?

The recall encompasses two distinct brands. Laboratoire Riva Inc. manufactures the affected acetaminophen caplets, while Life Brand—distributed through various retail partners—produces the affected melatonin tablets. Both products reached consumers through standard retail pharmacy channels and over-the-counter sales locations nationwide.

The distribution was not restricted to specific provinces; these items were available at the retail level across Canada. The over-the-counter status of both products means they were accessible without prescription, increasing the importance of consumer awareness regarding the specific lot numbers affected.

When Was the Acetaminophen Melatonin Recall Announced?

Health Canada issued the recall alert under reference RA-77279 following the identification of labelling discrepancies. The recall remains active as a Class II designation, indicating ongoing consumer-level action is required.

1. Quality monitoring identified labelling discrepancies in specific lots during routine compliance checks.
2. Health Canada classified the risk as Class II (moderate) and assigned alert number RA-77279.
3. Official notification posted to the Health Canada recall database.
4. Consumer and retailer notification distributed regarding specific lot numbers and return procedures.

What Information Is Definite About This Recall?

How Do Drug Recalls Work in Canada?

Health Canada oversees the recall of therapeutic products through a classification system that categorizes risk levels. Class II recalls, such as this acetaminophen and melatonin alert, indicate a situation where the use of, or exposure to, a product may cause temporary adverse health consequences. The system relies on manufacturers, distributors, and retailers to remove affected products from shelves while notifying consumers who may have purchased the items.

Over-the-counter products present unique challenges because they lack the prescription trail that facilitates direct patient notification. Consequently, public alerts and media coverage serve as the primary channels for consumer awareness. Health Canada’s recall procedures follow strict protocols to ensure public safety while maintaining proportionate response to the identified risk level. Home safety extends beyond medications to include appliances; for information on household equipment coverage, see Rheem Hot Water Tank – Warranty Coverage Guide.

What Health Authorities Say About the Recall

Health Canada has determined that this product is being recalled due to labelling errors that could lead to improper dosing. Consumers should verify their products against the affected lots immediately.

— Health Canada Recall Alert RA-77279

The regulatory authority emphasizes that while the risk is classified as moderate, the potential for under-treatment with acetaminophen or confusion with melatonin dosing warrants immediate consumer action. Compliance and enforcement protocols require firms to notify distributors and correct the labelling errors before returning products to market.

Summary of the Acetaminophen Melatonin Recall

Health Canada’s Class II recall targets specific lots of Riva Acetaminophen 500 mg (lot D3120) and Life Brand Timed Release Melatonin 10 mg (seven specific lots) due to labelling errors affecting tablet strength and dosing instructions. Consumers should verify their purchases against these lot numbers, consult healthcare providers before altering medication routines, and report any health concerns to Health Canada. The recall remains active with no adverse events reported to date.

Common Questions About the Recall